Suchergebnisse - Portal für Medizinische Datenmodelle (MDM-Portal)

Itemgruppen: Date of liver biopsy, Liver Biopsy size, Liver Biopsy Final Diagnosis, Liver Architecture, Description of Liver Cells or Hepatocytes, Liver Cell or Hepatocyte Inclusions or Vacuoles, Hepatocyte or Liver Cell Nuclear Abnormalities, Liver or Lobular Infiltrates, Portal Tract Inflammation, Bile Ducts, Portal Veins, Liver Infections, Liver: Parasites or Ova, Histologic Staining or Additional Studies Obtained

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Liver biopsy - Repeating form (Unscheduled/Dynamic visit)

A Parallel Group Study of Fluticasone Furoate/Vilanterol in Subjects with Asthma - 106837 - Liver Biopsy Data

- 07.12.18 - 1 Formular, 14 Itemgruppen, 108 Datenelemente, 1 Sprache

Itemgruppen: Date of liver biopsy, Biopsy size, Final diagnosis of biopsy, Liver architecture, Description of Liver Cells or Hepatocytes, Liver Cell or Hepatocyte Inclusions or Vacuoles, Hepatocyte or Liver Cell Nuclear Abnormalities, Liver or Lobular Infiltrates, Portal tract Inflamation, Bile ducts, Portal veins, Liver Infections, Parasites or Ova, Histologic Staining or Additional Studies Obtained

Study ID: 106837 Clinical Study ID: HZA106837 Study Title: A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01086384 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Relvar Study Indication: Asthma

Colorectal Cancer NCT00079274 Pathology - NCCTG Study N0147 Pathology Report Submission Form - 2542238v1.0 - NCCTG Study N0147 Pathology Report Submission Form

- 09.01.15 - 1 Formular, 1 Itemgruppe, 13 Datenelemente, 1 Sprache

Itemgruppe: Coversheet Module

NCCTG Study N0147 Pathology Report Submission Form Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=224E327A-2678-7307-E044-0003BA3F9857

Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphomas NCT00996593 - Central Pathology Assessment and Description

- 20.09.21 - 1 Formular, 7 Itemgruppen, 21 Datenelemente, 1 Sprache

Itemgruppen: Biopsy, Biopsy , Lymphoma, Non-Hodgkin | Classification, Pathologist evaluation | Central, Basis of Assessment, Pathologist evaluation | Central | Description, Administrative

Study ID: 104507 Clinical Study ID: BEX104507 Study Title: Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphoma Patients who have Previously Received Rituximab Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996593 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Cisplatin and Topotecan Recurrent or Persistent Carcinoma of the Cervix - 103369 - Pathology Report

- 31.12.19 - 1 Formular, 6 Itemgruppen, 20 Datenelemente, 1 Sprache

Itemgruppen: Administrative data, Primary, Histology Type, Histologic Grade, Specimens, Secondary

Study ID: 103369 Clinical Study ID: 103369 Study Title: A Randomized Phase III Study of Cisplatin Versus Cisplatin plus Topotecan Versus MVAC in Stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: Topotecan Study Indication: Cancer

GSK Ofatumumab in Waldenstrom Macroglobulinaemia, NCT00811733 - Histology

- 11.08.21 - 1 Formular, 3 Itemgruppen, 24 Datenelemente, 1 Sprache

Itemgruppen: Administrative Data, Waldenstrom's Histology, Lymphoplasmacytic lymphoma histology

Study ID: 110921 Clinical Study ID: 110921 Study Title: A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00811733 Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT00811733 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Ofatumumab Trade Name: N/A Study Indication: Waldenstrom Macroglobulinaemia The primary objective of this open-label, multi-center, Phase II study was to evaluate the safety and efficacy of Ofatumumab in subjects diagnosed with Waldenstrom Macroglobulinaemia. For the study, eligible subjects were enrolled to receive up to 3 cycles of treatment with Ofatumumab. The first cycle consisted of a single dose of 300 mg followed by 3 weekly doses of 1000 mg (Treatment Group A) or 4 weekly doses of 2000 mg (Treatment Group B) of Ofatumumab, with response assessment beginning at Week 12. Based on the Week 12-16 response, eligible subjects could receive up to 2 additional cycles of treatment. The different parts of this form have to be filled out at the Screening Visit and/or at unscheduled visits.

IHC Results, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - IHC Results, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

- 17.09.21 - 1 Formular, 2 Itemgruppen, 16 Datenelemente, 1 Sprache

Itemgruppen: Header, IHC Results

Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of Study: Results - IHC

Stichworte

Inhaltsverzeichnis

Ausgewählte Datenmodelle

Ewing Study Referenzhistopathologie DRKS00003588 - Referenzhistopathologie

TNM Staging GSK study Prostatic neoplasms NCT00883909

Local Pathology Results GSK study Prostatic neoplasms NCT00883909

Ewing Study Lokaler histopathologischer Befund DRKS00003588 - Lokaler histopathologischer Befund

Director's Challenge Lung Study Pathology Evaluation Form

Liver biopsy GSK study Chronic Coronary Heart Disease NCT00799903